Dr. Frederick Chen, MD

Cardiac Surgery  ·  
Male  ·  
Age 49
(8)
Insurances Accepted  ·  Save
Dr. Frederick Chen, MD
"I am an adult cardiac surgeon with significant professional activity in clinical care, laboratory research, resident teaching, and administration. With a full load of 200 surgeries annually, I am known for outstanding patient care in all New England. I am an extramurally (NIH and AHA) funded surgeon scientist. Previously, I was the Director of the Cardiac Surgery Research Laboratory at BWH. My research interest is applying engineering principles to cardiac surgery with an emphasis on heart failure. I estimate my clinical effort as 50%research 25%teaching 15%and administration as 10%. My Area of Excellence is Clinical Expertise and Innovation. I perform a full and complete spectrum of adult cardiac surgery, including valvular, coronary, and aortic surgery. I am known for meticulous patient care in the operating room and floor. I have promulgated selective antegrade cerebral perfusion at BWH, a technique for minimizing stroke risk during aortic surgery. I was RO1 funded and am currently AHA funded. I supervise typically 2-3 postdoctoral research fellows, a medical student, and a full time laboratory manager. There are probably less than five fully clinically active, extramurally funded cardiac surgeons nationally. I am investigating ventricular restraint, a new treatment for heart failure where the heart is wrapped with prosthetic material. I invented a method to apply restraint in an adjustable, measurable way. This work has resulted in the most comprehensive understanding of ventricular restraint. I am internationally known for this research. There is a patent pending on this methodology. My work is published in Circulation and Journal of Thoracic and Cardiovascular Surgery, the most important journals in cardiology and cardiovascular surgery. I have an interest in right heart failure and have recently been funded by the AHA for this work. I have an interest in functional, ischemic mitral regurgitation. I was the site PI (BWH) for the NIH funded cardiothoracic surgical trials in mitral regurgitation. I have significant contributions in Teaching and Education. I have always mentored at least two postdoctoral fellows at any one time. I strive to produce the academic surgeon who operates and performs research. My post-doctoral research fellows have won numerous research awards from the American College of Surgeons as well as prestigious national fellowships from the AHA, NIH, and Heart Failure Society. At BWH, all new cardiothoracic fellows in the BWH Thoracic Surgery Residency were trained by me as the first surgeon to teach them cardiac surgery. The ACGME residents have named this "Chen School," and have nominated me for five years straight for the McGoon Award, a prestigious annual national teaching award given to a single cardiothoracic surgeon educator who has finished training less than ten years ago. I won the McGoon Award this year and am nationally known for my teaching. I also have significant Administrative contributions. I contributed to cardiac surgical medical coding at BWHhave served on NIH study sectionsand am the senior thoracic surgeon on the American College of Surgeons Committee on Fundamental Surgical Problems. I have served on the Surgery Research Committee overseeing all surgical research at BWH and serve on the Animal Use Committee of HMS, overseeing all animal research in the Longwood Area. I was the Program Director for the BWH/Children's Hospital Thoracic Surgery Residency overseeing all ACGME thoracic surgery residents and I also manage all senior fellows as well. As Program Director, I successively led BWH to be approved by the Thoracic Surgery RRC of the ACGME for an Integrated 6 Year Thoracic Surgery Residency where residents are matched directly out of medical school. In summary, I have strived to be a multidimensional academic cardiac surgeon with significant and deep contributions in all areas of academic cardiac surgery."

Risks associated with the TAVR procedure include death, stroke and major bleeding

Important Risk Information for Patients

Indications:

The Edwards SAPIEN 3 transcatheter heart valve, model 9600TFX, and accessories are indicated for relief of aortic stenosis in patients with symptomatic heart disease due to severe native calcific aortic stenosis who are judged by a Heart Team, including a cardiac surgeon, to be at intermediate or greater risk for open surgical therapy (i.e., predicted risk of surgical mortality ≥ 3% at 30 days, based on the Society of Thoracic Surgeons (STS) risk score and other clinical co-morbidities unmeasured by the STS risk calculator).

The Edwards SAPIEN 3 transcatheter heart valve, model 9600TFX, and accessories are indicated for patients with symptomatic heart disease due to failure (stenosed, insufficient, or combined) of a surgical bioprosthetic aortic or mitral valve who are judged by a heart team, including a cardiac surgeon, to be at high or greater risk for open surgical therapy (i.e., predicted risk of surgical mortality ≥ 8% at 30 days, based on the STS risk score and other clinical co-morbidities unmeasured by the STS risk calculator).

Contraindications (Who should not use):

The Edwards SAPIEN 3 transcatheter heart valve and delivery system should not be used in patients who:

  • Cannot tolerate medications that thin the blood or prevent blood clots from forming.
  • Have an active infection in the heart or elsewhere.

Warnings:

  • There may be an increased risk of stroke in transcatheter aortic valve replacement procedures, compared to other standard treatments for aortic stenosis in the high or greater risk population.
  • If an incorrect valve size for your anatomy is used, it may lead to heart injury, valve leakage, movement, or dislodgement.
  • Patients should talk to their doctor if they have significant heart disease, a mitral valve device or are allergic to chromium, nickel, molybdenum, manganese, copper, silicon, and/or polymeric materials.
  • The SAPIEN 3 valve may not last as long in patients whose bodies do not process calcium normally.
  • During the procedure, your doctors should monitor the dye used in the body; if used in excess it could lead to kidney damage. X-ray guidance used during the procedure may cause injury to the skin, which may be painful, damaging, and long-lasting.
  • Transcatheter aortic heart valve patients should take medications that thin the blood or prevent blood clots from forming, except when likely to have an adverse reaction, as determined by their physician. The Edwards SAPIEN 3 transcatheter heart valve has not been tested for use without medications that thin the blood or prevent blood clots from forming.

Precautions:

The long-term durability of the Edwards SAPIEN 3 transcatheter heart valve is not known at this time. Regular medical follow-up is recommended to evaluate how well a patient’s heart valve is performing. Safety, performance, and durability of the SAPIEN 3 valve has not been established for placement inside a previously implanted transcatheter valve.

The safety and effectiveness of the transcatheter heart valve is also not known for patients who have:

  • An aortic heart valve that is not calcified, contains only one or two leaflets, has leaflets with large pieces of calcium that may block the vessels that supply blood to the heart or in which the main problem is that the valve leaks.
  • Previous prosthetic ring in any position.
  • Previous atrial septal occlude.
  • A heart that does not pump well, has thickening of the heart muscle, with or without blockage, unusual ultrasound images of the heart that could represent irregularities such as a blood clot, a diseased mitral valve that is calcified or leaking, or Gorlin syndrome, a condition that affects many areas of the body and increases the risk of developing various cancers and tumors.
  • Low white, red or platelet blood cell counts, or history of bleeding because the blood does not clot properly.
  • Diseased, abnormal or irregularly shaped vessels leading to the heart. Vessels which are heavily diseased or too small for associated delivery devices, or a large amount of calcification at the point of entry.
  • Allergies to blood-thinning medications or dye injected during the procedure.
  • For a valve in valve procedure, there is a risk of leakage if the previously implanted tissue valve is not securely in place or if it is damaged. There is also the possibility that a partially detached valve leaflet from the previously implanted valve could block a blood vessel.
  • Additional pre-procedure imaging will be completed to evaluate proper sizing.

Potential risks associated with the procedure include:

  • Death, stroke, paralysis (loss of muscle function), permanent disability, or severe bleeding.
  • Risks to the heart, including heart attack or heart failure, a heart that does not pump well, irregular heartbeat that may result in a need for a permanent pacemaker, chest pain, heart murmur, false aneurysm, recurring aortic stenosis(narrowing), too much fluid around the heart, injury to the structure of the heart.
  • Risks to your lungs or breathing, including difficulty breathing, fainting, buildup of fluid in or around the lungs, weakness or inability to exercise.
  • Risks involving bleeding or your blood supply, including formation of a blood clot, high or low blood pressure, limited blood supply, a decrease in red blood cells, or abnormal lab values, bleeding in the abdominal cavity, collection of blood under the skin.
  • Additional risks, including life-threatening infection, dislodgement of calcified material, air embolism (air bubbles in the blood vessels), poor kidney function or failure, nerve injury, fever, allergic reaction to anesthesia or dye, reoperation, pain, infection or bleeding at incision sites, or swelling.

Additional potential risks specifically associated with the use of the heart valve include:

  • Valve movement after deployment, blockage or disruption of blood flow through the heart, need for additional heart surgery and possible removal of the SAPIEN 3 valve, a blood clot that requires treatment, damage to the valve (e.g., wear, breakage, recurring aortic stenosis), nonstructural valve dysfunction (e.g., leakage, inappropriate sizing or positioning, blockage, excess tissue in growth, blood cell damage, etc.) or mechanical failure of the delivery system and/or accessories.

CAUTION: Federal (United States) law restricts these devices to sale by or on the order of a physician.

Edwards, Edwards Lifesciences, the stylized E logo, Edwards SAPIEN, Edwards SAPIEN 3, SAPIEN, and SAPIEN 3 are trademarks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners.

© 2017 Edwards Lifesciences Corporation. All rights reserved. PP--US-2507 v1.0

Edwards Lifesciences One Edwards Way, Irvine CA 92614 USA edwards.com

75 Francis St

Boston, MA 02115

Contact Information

(617) 732-5500

Dr. Frederick Chen, MD

Dr. Frederick Chen, MD

Accepted insurance

  • Aetna
  • Blue Cross Blue Shield
  • Blue Cross Blue Shield of Louisiana
  • Blue Cross Blue Shield of Massachusetts
  • Cigna
  • Harvard Pilgrim Health Care
  • MultiPlan
  • Tufts Health Plan

*Please verify this information when scheduling an appointment.

Learn about Dr. Chen

Be confident in your decisions by checking out your provider's top areas of care, education, patient reviews and more. Learn about finding the right doctor for you.

Top Care Areas

See how frequently Dr. Chen performs your care needs compared to other doctors.

Valve Repair or Replacement (Aortic, Mitral, Tricuspid, and Pulmonary)
normal
more than 71% of peers
Coronary Artery Disease (CAD)
normal
more than 69% of peers
Vascular Disease
normal
more than 68% of peers

Dr. Chen's percentages are based on the rate of treatment compared to peers nationwide from insurance data. Learn more info about our data and this Top Care Areas component.

Dr. Chen's bio

This content was provided by Dr. Chen "I am an adult cardiac surgeon with significant professional activity in clinical care, laboratory research, resident teaching, and administration. With a full load of 200 surgeries annually, I am known for outstanding patient care in all New England. I am an extramurally (NIH and AHA) funded surgeon scientist. Previously, I was the Director of the Cardiac Surgery Research Laboratory at BWH. My research interest is applying engineering principles to cardiac surgery with an emphasis on heart failure. I estimate my clinical effort as 50%research 25%teaching 15%and administration as 10%. My Area of Excellence is Clinical Expertise and Innovation. I perform a full and complete spectrum of adult cardiac surgery, including valvular, coronary, and aortic surgery. I am known for meticulous patient care in the operating room and floor. I have promulgated selective antegrade cerebral perfusion at BWH, a technique for minimizing stroke risk during aortic surgery. I was RO1 funded and am currently AHA funded. I supervise typically 2-3 postdoctoral research fellows, a medical student, and a full time laboratory manager. There are probably less than five fully clinically active, extramurally funded cardiac surgeons nationally. I am investigating ventricular restraint, a new treatment for heart failure where the heart is wrapped with prosthetic material. I invented a method to apply restraint in an adjustable, measurable way. This work has resulted in the most comprehensive understanding of ventricular restraint. I am internationally known for this research. There is a patent pending on this methodology. My work is published in Circulation and Journal of Thoracic and Cardiovascular Surgery, the most important journals in cardiology and cardiovascular surgery. I have an interest in right heart failure and have recently been funded by the AHA for this work. I have an interest in functional, ischemic mitral regurgitation. I was the site PI (BWH) for the NIH funded cardiothoracic surgical trials in mitral regurgitation. I have significant contributions in Teaching and Education. I have always mentored at least two postdoctoral fellows at any one time. I strive to produce the academic surgeon who operates and performs research. My post-doctoral research fellows have won numerous research awards from the American College of Surgeons as well as prestigious national fellowships from the AHA, NIH, and Heart Failure Society. At BWH, all new cardiothoracic fellows in the BWH Thoracic Surgery Residency were trained by me as the first surgeon to teach them cardiac surgery. The ACGME residents have named this "Chen School," and have nominated me for five years straight for the McGoon Award, a prestigious annual national teaching award given to a single cardiothoracic surgeon educator who has finished training less than ten years ago. I won the McGoon Award this year and am nationally known for my teaching. I also have significant Administrative contributions. I contributed to cardiac surgical medical coding at BWHhave served on NIH study sectionsand am the senior thoracic surgeon on the American College of Surgeons Committee on Fundamental Surgical Problems. I have served on the Surgery Research Committee overseeing all surgical research at BWH and serve on the Animal Use Committee of HMS, overseeing all animal research in the Longwood Area. I was the Program Director for the BWH/Children's Hospital Thoracic Surgery Residency overseeing all ACGME thoracic surgery residents and I also manage all senior fellows as well. As Program Director, I successively led BWH to be approved by the Thoracic Surgery RRC of the ACGME for an Integrated 6 Year Thoracic Surgery Residency where residents are matched directly out of medical school. In summary, I have strived to be a multidimensional academic cardiac surgeon with significant and deep contributions in all areas of academic cardiac surgery."
Less
Read Less

2  Specialties

  • Cardiac Surgery
  • Adult Cardiac Surgery

1  Board Certifications

  • Thoracic Cardiovascular Surgery
    Accredited by: American Board of Thoracic Surgery*

42  Conditions Treated

  • Aneurysm
  • Aneurysm of Heart
  • Angina and Acute Coronary Syndrome
  • Aortic Aneurysm
  • Aortic Dissection
  • Aortic Ectasia
  • Aortic Stenosis
  • Aortic Valve Disease
  • Aortic Valve Regurgitation
  • Arrhythmias
  • Atrial Fibrillation
  • Atrial Flutter
  • Benign Tumor
  • Cancer
  • Cardiomegaly
  • Cardiomyopathy
  • Carotid Artery Disease
  • Congenital Aortic Valve Disorders
  • Congenital Heart Defects
  • Congenital Heart Disease
  • Congestive Heart Failure
  • Coronary Artery Disease (CAD)
  • Empyema
  • Endocarditis
  • Heart Attack (Acute Myocardial Infarction)
  • Heart Disease
  • Heart Tumors, Benign
  • Lung Cancer
  • Mitral Valve Disease
  • Mitral Valve Regurgitation
  • Mitral Valve Stenosis
  • Neuroendocrine Tumors
  • Pericardial Disease
  • Peripheral Arterial Aneurysm and Dissection
  • Pulmonary Disease
  • Pulmonary Embolism
  • Pulmonary Valve Disease
  • Rheumatic Aortic Valve Disorders
  • Septal Defect
  • Thrombosis
  • Thymomas
  • Vascular Disease
Less
Read Less

40  Procedures

Less
Read Less

Background Check

0 Malpractice Claims

No malpractice history found for Massachusetts.

0 Sanctions

No sanctions history found for the years that Healthgrades collects data.

0 Board Actions

No board actions found for the years that Healthgrades collects data.

Education

  • Harvard Med Sch
    Medical School | Graduated 1995
  • Brigham and Womens Hospital
    Residency Hospital | Completed 2002
  • Massachusetts General Hospital
    Residency Hospital | Completed 2004

Awards & Recognition

Awards & Honors
  • Healthgrades Honor Roll
Media & Publications

Dr. Chen has no media or publications listed.

Languages Spoken

  • English

Memberships & Professional Affiliations

Dr. Chen does not have any memberships or affiliations listed. If you are Dr. Chen and would like to add memberships or affiliations, please update your profile.

Dr. Chen's Reviews

Likelihood to recommend Dr. Chen

5.0

Based on 8 reviews

5 Stars
100%
(8)
4 Stars
0%
(0)
3 Stars
0%
(0)
2 Stars
0%
(0)
1 Star
0%
(0)

Leave a review

How likely are you to recommend
Dr. Chen?
(Select your rating)
Average Wait Time
  • 10 – 15 minutes
Dr. Chen's Performance
  • Trustworthiness
  • Explains condition(s) well
  • Answers questions
  • Time well spent
Office & Staff Performance
  • Scheduling
  • Office environment
  • Staff friendliness

Leave a review

How was your experience with Dr. Chen?

Locations

Insurance accepted

Accepted insurance can change. Please double-check when making an appointment.

Aetna
Aetna HMO
Choice Plus POS II
Blue Cross Blue Shield
Blue Card PPO
Blue Cross Blue Shield of Louisiana
BlueConnect HMO
Blue Cross Blue Shield of Massachusetts
Preferred Blue PPO
Cigna
Cigna HMO
Cigna PPO
LocalPlus
Open Access Plus
Harvard Pilgrim Health Care
Harvard Pilgrim Health Care PPO
MultiPlan
PHCS Network PPO
Tufts Health Plan
Tufts PPO

Affiliated Hospitals

Check the quality of care at hospitals Dr. Chen is affiliated with. For more detailed ratings based on patient outcomes, view the hospital's profile.

Learn more